145 related articles for article (PubMed ID: 35173090)
41. Massive ascites caused by peritoneal extramedullary hematopoiesis as the initial manifestation of myelofibrosis.
Hung SC; Huang ML; Liu SM; Hsu HC
Am J Med Sci; 1999 Sep; 318(3):198-200. PubMed ID: 10487412
[TBL] [Abstract][Full Text] [Related]
42. Subcutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis following polycythemia vera.
Tanaka M; Kanamori H; Yamaji S; Mishima A; Yamazaki E; Taguchi J; Aoba M; Fujisawa S; Mohri H; Ishigatsubo Y
Leuk Lymphoma; 2001 Jan; 40(3-4):437-40. PubMed ID: 11426569
[TBL] [Abstract][Full Text] [Related]
43. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.
Gilles L; Arslan AD; Marinaccio C; Wen QJ; Arya P; McNulty M; Yang Q; Zhao JC; Konstantinoff K; Lasho T; Pardanani A; Stein B; Plo I; Sundaravel S; Wickrema A; Migliaccio A; Gurbuxani S; Vainchenker W; Platanias LC; Tefferi A; Crispino JD
J Clin Invest; 2017 Apr; 127(4):1316-1320. PubMed ID: 28240607
[TBL] [Abstract][Full Text] [Related]
44. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
45. [Cutaneous extramedullary hematopoiesis in idiopathic myelofibrosis. Description of a case].
Del Forno C; Borroni G; Caresana G; Nalli G; Barosi G
G Ital Dermatol Venereol; 1990 May; 125(5):205-9. PubMed ID: 2253954
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous myelofibrosis.
Hoss DM; McNutt NS
J Cutan Pathol; 1992 Jun; 19(3):221-5. PubMed ID: 1357014
[TBL] [Abstract][Full Text] [Related]
47. Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients.
Ojeda-Uribe M; Morel O; Ungureanu C; Desterke C; Le Bousse-Kerdilès MC; Boulahdour H
Cancer Med; 2016 Sep; 5(9):2378-84. PubMed ID: 27518041
[TBL] [Abstract][Full Text] [Related]
48. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly.
Wolf BC; Neiman RS
Blood; 1985 Apr; 65(4):803-9. PubMed ID: 3978228
[TBL] [Abstract][Full Text] [Related]
49. Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis.
Wei XQ; Zheng ZH; Jin Y; Tao J; Abassa KK; Wen ZF; Shao CK; Wei HB; Wu B
World J Gastroenterol; 2014 Sep; 20(33):11921-6. PubMed ID: 25206301
[TBL] [Abstract][Full Text] [Related]
50. Sclerosing Extramedullary Hematopoietic Tumor: A Case Report.
Wang D; Castro E; Rao A; McPhaul CM
J Investig Med High Impact Case Rep; 2020; 8():2324709620956463. PubMed ID: 32911987
[TBL] [Abstract][Full Text] [Related]
51. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
[TBL] [Abstract][Full Text] [Related]
52. Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders.
O'Malley DP; Kim YS; Perkins SL; Baldridge L; Juliar BE; Orazi A
Mod Pathol; 2005 Dec; 18(12):1550-61. PubMed ID: 16118626
[TBL] [Abstract][Full Text] [Related]
53. Agnogenic myeloid metaplasia in children.
Mallouh AA; Sa'di AR
Am J Dis Child; 1992 Aug; 146(8):965-7. PubMed ID: 1636666
[TBL] [Abstract][Full Text] [Related]
54. [Splenectomy in osteomyelofibrosis. Indications and outcome].
Böhner H; Rötzscher VM; Tirier C; Heit W; Greiner J
Chirurg; 1996 Oct; 67(10):1016-9. PubMed ID: 9011420
[TBL] [Abstract][Full Text] [Related]
55. Diabetes insipidus caused by extramedullary hematopoiesis.
Badon SJ; Ansell J; Smith TW; Coslovsky R; Gill L; Woda BA
Am J Clin Pathol; 1985 Apr; 83(4):509-12. PubMed ID: 3984946
[TBL] [Abstract][Full Text] [Related]
56. Modern management of splenomegaly in patients with myelofibrosis.
Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
[TBL] [Abstract][Full Text] [Related]
57. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature.
Jantunen E; Hänninen A; Naukkarinen A; Vornanen M; Lahtinen R
Am J Hematol; 1994 Jul; 46(3):218-24. PubMed ID: 8192152
[TBL] [Abstract][Full Text] [Related]
58. [Blastic crisis of primary myelofibrosis associated with multiple myeloblastomas ].
Fukushima T; Uchida M; Iwasaki H; Kamiya K; Tanaka T; Yoshimura T; Sasaki K; Tsutani H; Wano Y; Takayama H
Rinsho Ketsueki; 1990 Jan; 31(1):95-9. PubMed ID: 2313911
[TBL] [Abstract][Full Text] [Related]
59. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
60. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
